We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators.
- Authors
Mlyuka, Hamu J.; Kilonzi, Manase; Mutagonda, Ritah F.; Chirande, Lulu; Mikomangwa, Wigilya P.; Myemba, David T.; Sambayi, Godfrey; Mwakawanga, Dorkasi L.; Ndunguru, Joyce; Jonathan, Agnes; Makani, Julie; Ruggajo, Paschal; Minja, Irene K.; Balandya, Emmanuel; Kamuhabwa, Appolinary A. R.
- Abstract
Despite three decades of proven safety and effectiveness of hydroxyurea in modifying sickle cell disease (SCD), its accessibility is limited in Sub-Saharan Africa, which shares 75% of the world's SCD burden. Therefore, it is time to explore the barriers and facilitators for manufacturing and importation of hydroxyurea for SCD in Tanzania. This was qualitative research that employed a case study approach. Purposive sampling followed by an in-depth interview (IDI) using a semi-structured questionnaire aspired by data saturation enabled us to gather data from 10 participants. The study participants were people with more than three years of experience in pharmaceuticals importation, manufacturing, and regulation. The audio-recorded data were verbatim transcribed and analyzed using thematic analysis. Two themes were generated. The first comprised barriers for importation and manufacturing of hydroxyurea with sub-themes such as inadequate awareness of SCD and hydroxyurea, limited market, and investment viability. The second comprised opportunities for importation and manufacturing of hydroxyurea with sub-themes such as awareness of activities performed by medicines regulatory authority and basic knowledge on SCD and hydroxyurea. Inadequate understanding of SCD, hydroxyurea, and orphan drug regulation are major issues that aggravate the concern for limited market and investment viability. Existing opportunities are a starting point towards increasing the availability of hydroxyurea.
- Subjects
TANZANIA; DRUG therapy for sickle cell anemia; HEALTH services accessibility; INVENTORY shortages; HYDROXYUREA; RESEARCH methodology; MEDICAL supplies; INTERVIEWING; SUPPLY chains; QUALITATIVE research; DRUGS; CASE studies; RESEARCH funding; PHARMACEUTICAL industry; JUDGMENT sampling; THEMATIC analysis
- Publication
Healthcare (2227-9032), 2022, Vol 10, Issue 11, p2223
- ISSN
2227-9032
- Publication type
Article
- DOI
10.3390/healthcare10112223